CLASS III ONGOING Drug recall · Reported 5 Nov 2025 · FDA Enforcement Report

Everolimus tablets 5 mg (each carton contains 4 blister recalled

Endo USA is recalling Everolimus tablets 5 mg (each carton contains 4 blister strips with each), distributed nationwide in the US. The recall was initiated on 10 Oct 2025 and the FDA has classified it as Class III.

Check your package

Lot, batch or date codesLot #: 550172201, Exp. Date JAN-26; 550184801, Exp. Date MAR-26; 550204001, Exp. Date JUL-26
Quantity recalled2,035 cartons

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0142-2026
FDA event ID
97866
Recalling firm
Endo USA, Malvern, PA
Classification
Class III
Status
Ongoing
Recall initiated
10 Oct 2025
FDA classified
29 Oct 2025
Reported
5 Nov 2025
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

10 Oct 2025Recall initiated by company
29 Oct 2025Classified by FDA+19 days
5 Nov 2025Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Everolimus tablets 2.5 mg, 28 tablets (each carton contains 4 blister strips with 7 tablets each), Rx only, Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977 NDC# 49884-119-91

Where it was distributed

Nationwide within the United States

Nationwide

Questions about this recall

Is Everolimus tablets 5 mg (each carton contains 4 blister strips with each) recalled?

Yes. Endo USA recalled Everolimus tablets 5 mg (each carton contains 4 blister strips with each) on 10 Oct 2025. The recall is Class III and its status is Ongoing. Recall number D-0142-2026.

Why was it recalled?

Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.

Which lots are affected?

Lot #: 550172201, Exp. Date JAN-26; 550184801, Exp. Date MAR-26; 550204001, Exp. Date JUL-26

Where was it sold?

Nationwide within the United States

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class III mean?

Class III recalls are for products unlikely to cause any adverse health consequence, usually labelling or quality issues.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Endo USA

All 11

Other Everolimus recalls

All 5